PACTR202209903019732招募中2 期
Bosentan and Sildenafil in Pulmonary Hypertension in Cardiac Anesthesia: Mansoura Novel Strategy
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)（—）
- 性别
- All
入选标准
- •1.American Society of Anesthesiologists physical status grade II and ?.
- •2.Age between 20 and 70 years.
- •3.either gender.
- •4.Systolic pulmonary artery pressure greater than 70 mmHg.
排除标准
- •1.Patient refusal.
- •2.Uncompensated cardiac disease.
- •3.Severe chronic obstructive pulmonary disease ( COPD) and bronchial asthma.
- •4.Chest infection.
- •5.uncontrolled HTN and DM.
- •6.Preoperative liver and renal disease.
- •7.Body Mass Index > 40 Kg/m2.
- •8.Hematologic disorders.
- •9.Neuromuscular disorders.
- •Redo and urgent surgeries.
研究者
相似试验
进行中（未招募）
1 期
Racecadotril used in combination with sildenafil to reduce blood pressure in the lungs.Pulmonary hypertensionMedDRA version: 14.1 Level: PT Classification code 10037400 Term: Pulmonary hypertension System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2012-003921-13-GBniversity College London21
进行中（未招募）
1 期
BOsentan for Mild Pulmonary vascular disease in Asd patients (the BOMPA trial): a double-blind, randomized controlled, pilot trial - BOMPA trialEUCTR2010-020209-33-BEniversity Hospitals Leuven20
进行中（未招募）
不适用
Betablocker Therapy in Pulmonary Arterial HypertensioEUCTR2010-020424-21-NLVU medical center
已完成
2 期
Betablocker Therapy in Pulmonary Arterial Hypertensioidiopathische pulmonale hypertensiehigh bloodpressure pulmonary vascular system10019280pulmonary hypertensionNL-OMON34177Vrije Universiteit Medisch Centrum30
进行中（未招募）
不适用
SPHERIC-1OE: study of the duration of 12 months for the observation of the use of sildenafil for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease in patients enrolled in the previous study titled SPHERIC-1EUCTR2011-002018-35-ITASSOCIAZIONE ITALIANA PNEUMOLOGI OSPEDALIERI